Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Inhibition of leukocyte migration in agarose-agar was used as a probe for tumor-associated antigen in 3-M KCl solubilized extracts of gastric, colon, and lung cancers from humans. Twelve of 40 (30%) leukocyte preparations from gastric cancer patients, 10 of 21 (48%) from colon cancer patients, and 7 of 14 (50%) from lung cancer patients were inhibited by their respective histologically homologus cancer extract. However, among 75 preparations from various cancer patients, leukocytes from only 2 gastric cancer patients were inhibited by paired normal gastric tissue extracts. Only 2 of 68 preparations from normal individuals and none of 67 preparations from patients with nonmalignant diseases, such as gastric peptic ulcer, gastritis, colon polyposis, colitis, pulmonary tuberculosis, chronic bronchitis, and sarcoidosis, were inhibited by cancer extracts. These findings suggest the presence in KCl extracts of gastric cancer of presumed tumor-associated antigen(s) that is antigenically distinct from that of either colon or lung cancer.
 ...
PMID:Inhibition of human leukocyte migration in agar by 3-M potassium chloride extracts of stomach, colon, and lung cancers. 28 34

Sera from 134 selected patients with various types of cancer were tested for soluble antigen-antibody complexes by the C1q binding method. Sera from 85 healthy blood bank donors served as normal controls. C1q binding activity (C1q BA) values above the 95th percentile for healthy subjects were found in 83% of sera from patients with neoplastic diseases. The incidence of abnormal C1q BA values among patients with malignant melanoma was 83%, with breast cancer 74%, with colon cancer 75%, with lung cancer 88%, with leukemia and lymphoma 85%, and with miscellaneous tumors 94%. High C1q BA values were found most frequently in sera of patients who had been diagnosed relatively recently (within 5 mo) and who had evident residual disease after surgical treatment. Recurrence or progression of tumor growth occurred significantly more frequently in lung cancer patients with high C1q BA. DNA was not detected in cancer patients' sera and treatment with DNase did not decrease in C1q BA. C1q BA in sera could not be explained by the presence of antiglobulin antibodies. Sucrose density gradient ultracentrifugation studies of the serum C1q BA in 4 cancer patients showed that the major binding activity was found between 19S and 7S.
 ...
PMID:The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. 32 5

Charts of 437 patients having plasma carcinoembryonic antigen determinations during the period January 1, 1976 through April 30, 1976 were reviewed to determine whether CEA results led to clinical decisions altering management patterns. Data analysis disclosed that CEA test results did not result in any change in management in 167 patients with non-neoplastic disease. Most had single determinations. In 270 patients with neoplastic disease, CEA results led to changes in management in one patient with lung cancer and two patients with colon cancer, which may have altered prognosis. In a fourth patient, CEA results led to discovery of unresectable pancreatic cancer at laparotomy. Cost benefit analysis indicated a CEA test cost of $5,047.50 per patient benefitted in 299 patients eligible for analysis. We conclude that maximal benefit to the patient results from serial CEA test use in follow-up of colon cancer patients after curative therapy.
 ...
PMID:The use and abuse of CEA test in clinical practice. 41 1

The recording of new cases of cancer in the Bas-Rhin department interest about 883 000 persons in 1975. 3 073 cancer cases have been registered. The data show an incidence of 424 per 100 000 for male population and 309 per 100 000 among female population. Among male population: lung cancer is the most frequent, it represents 17.1 per cent of male cancers with an incidence of 72.5. In second position cancer of the rectum and recto-sigmoid which represents 7.9 per cent of cancers; it has an incidence of 33.4 per cent. Then followed in this order: prostate cancer with an incidence of 32.3, colon cancer with an incidence of 30.1, cancer of the stomach, and bladder. Among female population: breast cancer is by far the most frequent, it represents 27.5 per cent of all cancers, the incidence is 88.4; next corpus uteri cancer with an incidence of 29.5; colon cancer with an incidence of 25.4, followed by cervix uteri cancer with an incidence of 22.1. The genital localizations, on the whole represent 23.2 per cent of cancers with an incidence of 75.3. It is too early to interprete the recorded disparities among the different districts, nevertheless, one can think that the low rates reported in some districts is due to an under-recording.
 ...
PMID:[Incidence of new cases of cancer in 1975 in the Department of Bas-Rhin]. 66 79

Mononuclear cells from 115 individuals were tested in a 4-h chromium release assay against two breast-cancer-derived cell lines, G11 and MCF-7, and a myeloid line, K-562, shown previously to be sensitive to natural cytotoxicity. These data were analyzed in a manner designed to detect hyperreactivity against the breast cell lines relative to the level of reactivity against K-562. A high proportion of breast cancer patients were found to be relatively hyperreactive against G11 (12/18 or 67%) and against MCF-7 (10/18 or 56%). Fibroadenoma patients were very similar to the normal females, with 0/11 hyperreactive to G11 and 1/11 (9%) to MCF-7. However, several normal males (7/17 or 41%) were hyperreactive to G11 but not to MCF-7 (2/17 or 12%). Colon cancer and lung cancer patients were also more hyperreactive to G11, 4/8 or 50% and 4/6 or 67%, respectively, than they were to MCF-7, 1/8 or 13% and 1/6 or 17%, respectively. Only fibrocystic patients resembled the breast cancer patients, with some but not as many individuals being hyperreactive to G11 (3/8 or 38%) and to MCF-7 (2/8 or 25%). With another group of individuals reproducibility of the method was demonstrated, with only 1/14 or 7% of normal females and 12/17 or 70% of breast cancer patients being hyperreactive to G11. Thus, natural cytotoxicity toward K-562 can be related to breast cancer-associated cytotoxicity toward MCF-7 in a way that distinguishes a majority of breast cancer patients specifically from other groups of individuals.
 ...
PMID:Relationship of human natural lymphocyte-mediated cytotoxicity to cytotoxicity of breast-cancer-derived target cells. 84 17

Serum RNase (ribonuclease) of normal persons and of patients with pancreatitis, carcinoma of pancreas, or other neoplasms was determined with poly(C) as substrate. Strikingly abnormal elevations occur in the serum RNase of patients with pancreatic cancer. There is no elevation in the serum RNase level of patients with pancreatitis. Average serum RNase values of 52 normal persons, 10 patients with pancreatitis, 30 patients with pancreatic cancer, 28 patients with breast cancer, 11 patients with lung cancer, 20 patients with colon cancer, six patients with stomach cancer, and four patients with liver cancer, respectively, were 104, 120, 383, 131, 173, 197, 194, and 152 units/ml of serum. Ninety percent of the patients with pancreatic cancer were above the level of 250 units of serum and 90% of all patients with varied cancers were below this level. In the presence of severe renal insufficiency, marked elevation of serum RNase was also observed. Serum RNase, because of its unique specificity, pancreatic origin, and its abnormal elevation in sera of patients with pancreatic cancer, serves as a reliable biochemical marker of carcinoma of the pancreas in the presence of normal renal function.
 ...
PMID:Elevated serum ribonuclease in patients with pancreatic cancer. 106 80

The published studies of cancer of United States Jews are reviewed. Despite the lack of religious designation on death certificates, case reports, and census returns, a number of indirect methods for measuring the problem have been devised, which produce fairly consistent findings. In general, for American Jews, these show deficits in cancer mortality, among males, for the buccal cavity and pharynx and prostate and, among females, for the breast, uterine cervix and corpus, and bladder. Excesses in mortality, noted for both sexes, are esophagus, stomach, colon, pancreas, lymphomas, and leukemia and, in females, the lung and the ovary. The standardized mortality ratios for cancer of selected sites for Russian-born residents of upstate New York, 1969 through 1971, are presented as an indirect measure of the problem in the United States Jews. Statistically significant excesses were found in males for stomach and colon, with a striking deficit in cancer of the buccal cavity and pharynx. Among females, excesses were noted for stomach, pancreas, and lung with a sharp deficit in the uterine cervix. On the basis of the religious affiliation of the cemetery of burial, estimates of the Jewish and non-Jewish components of the 800 deaths in Russian-born residents were determined. Expected deaths in these two subgroups by sex, for each cancer site, were then calculated by use of the site-specific proportionate mortality of upstate New York for these years. This revealed a significant excess among Jewish males for colon cancer, with a deficit in lung cancer, while among the non-Jewish male components stomach cancer mortality was the only site significantly in excess. Among Jewish females, stomach and lung cancers were in excess, with a deficit in cancers of the breast and cervix uteri. In non-Jewish Russian-born females, the only site significantly in excess was stomach, with breast cancer showing a deficit.
 ...
PMID:Cancer in United States Jews. 119 15

A non-concurrent prospective study was made on deaths from cancer and other causes occurring among 2,675 male workers at a metal refinery from 1949 to 1971. The expected number of deaths computed by applying age- and cause-specific death rates of Japanese males to these workers was compared with the observed number of deaths. Among 839 copper smelters, significantly increased mortalities were noted for lung cancer (SMR = 1,189) and colon cancer, but nor for cancer of the stomach, liver (primary) and biliary passages, pancreas and skin or for leukemia, tuberculosis, cerebrovascular diseases, heart diseases and liver cirrhosis. A dose-response relationship was demonstrated between the mortality from lung cancer and the degree of exposure. A very high excess mortality from lung cancer (SMR = 2,500) was seen among copper smelters who were considered to have been most heavily exposed to arsenic or workers who had engaged in sintering and blast furnace operations for 15 years of more before 1949. The latent period of lung cancer was 37.6 years on average, and not related to level of exposure. Twenty-six of 29 deaths from lung cancer among copper smelters occurred after they had left the refinery. Other production workers and clerical workers showed no significant excess mortality from any kind of cancer.
 ...
PMID:A cohort study on mortality from cancer and other causes among workers at a metal refinery. 125 55

This paper describes the progressive changes in cancer incidence that have been observed among Japanese after their migration to Hawaii. It reviews descriptive and analytic epidemiologic data suggesting a role for genetic susceptibilities in explaining the high risk of Japanese for colon cancer and their low risk for lung cancer, when compared to Caucasians. Differences in certain pharmacogenetic polymorphisms may explain these risk patterns. This research may lead to a better characterization of cancer risk at the individual level and, consequently, to improved methods of prevention.
 ...
PMID:[Cancer in Japanese migrants to Hawaii: interaction between genes and environment]. 128 41

Antitumor polyoxomolybdates have been recognized in the course of study on the medical utilization of polyoxometalates, inorganic polymers of metal oxide. [NH3Pri]6[Mo7O24].3H2O (PM-8) was found as a representative of antitumor polyoxomolybdates. The growth suppressions of PM-8 against Co-4 human colon cancer xenografted under the subrenal capsule in cd-1 mice were equal or superior to that of 5-FU, MMC, ACNU, ADM and CDDP. Potent antitumor activity of PM-8 is also established against MX-1 human breast and OAT human lung cancer xenografted in athymic nude mice. Polyoxomolybdate is a new type of antitumor substance.
 ...
PMID:Antitumor activity of new antitumor substance, polyoxomolybdate, against several human cancers in athymic nude mice. 130 30


1 2 3 4 5 6 7 8 9 10 Next >>